← FDA DRUG APPROVALS

FDA ANDA · ANDA204354

MESALAMINE

Sponsor: QUAGEN

APPLICATION
ANDA204354
TYPE
ANDA
ORIGINAL APPROVAL
2015-11-24
LATEST ACTION
2024-11-07
ROUTE
RECTAL
DOSAGE FORM
SUPPOSITORY
MARKETING STATUS
Prescription

Products

MESALAMINEPrescription
MESALAMINE 1GM · SUPPOSITORY · RECTAL

Approval history

2024-11-07Labeling · Supplement 8 · standardAP
2023-09-12Labeling · Supplement 7 · standardAP
2023-09-12Labeling · Supplement 5 · standardAP
2023-09-12Labeling · Supplement 1 · standardAP
2023-09-12Labeling · Supplement 6 · standardAP
2023-09-12Labeling · Supplement 2 · standardAP
2015-11-24UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →